SCHEMBL2015384

SCHEMBL2015384

CN1CCN2c3cccc(F)c3OCC[C@H]2C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.42
DRD2 P14416 2/20 0.41
AVPR1A P37288 1/20 0.39
ADRA2A P08913 2/20 0.36
PIK3CD O00329 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
HTR2A P28223 3/20 0.35
LMNA P02545 2/20 0.35
HTR2C P28335 2/20 0.35
HTR2B P41595 2/20 0.35
MEN1 O00255 2/20 0.35
TP53 P04637 2/20 0.35
CYP3A4 P08684 2/20 0.35
KMT2A Q03164 2/20 0.35
HTR6 P50406 2/20 0.35
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2015572 0.89 DRD2 (0.41) SOS1DRD2ADRA2APIK3CDHTR2A
SCHEMBL2020083 0.83 DRD3 (0.40) SOS1DRD2AVPR1AADRA2ACYP2D6
SCHEMBL2016220 0.79 SOS1 (0.41) SOS1DRD2ADRA2AHTR2ALMNA
SCHEMBL696852 0.79 SOS1 (0.41) SOS1DRD2ADRA2AHTR2ALMNA
SCHEMBL2019235 0.77 HTR2C (0.52) HTR2AHTR2CHTR2B
SCHEMBL2015836 0.77 HTR2C (0.52) HTR2AHTR2CHTR2B
SCHEMBL2014411 0.76 SOS1 (0.39) SOS1DRD2AVPR1ACYP2D6CYP2C9
SCHEMBL20328102 0.73 AVPR1A (0.41) DRD2AVPR1APIK3CDPIK3CBPIK3CG
SCHEMBL30962043 0.73 SCN9A (0.44) AVPR1APIK3CDPIK3CBPIK3CGHTR2C
SCHEMBL2565554 0.73 DRD2 (0.44) SOS1DRD2ADRA2AHTR2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3150607-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF AbbVie Inc. (US) 2017-04-05 EP claimed
EP-2560973-B1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBVIE INC (US) 2016-11-16 EP claimed
US-20110130382-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2011-06-02 US claimed
EP-3150607-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF AbbVie Inc. (US) 2017-04-05 EP disclosed
EP-2560973-B1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBVIE INC (US) 2016-11-16 EP disclosed
US-8546377-B2 Modulators of 5-HT receptors and methods of use thereof ABBVIE INC. (US) 2013-10-01 US disclosed
EP-2560973-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF Abbvie Inc. (US) 2013-02-27 EP disclosed
WO-2011133182-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2011-10-27 WO disclosed
US-20110130382-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130382-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF HTR4, HTR1A, HTR1D SOS1 2286/4885DRD2 73/4885AVPR1A 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.